In 1998, the Tunisian team of the 'Centre National de Greffe de Moelle Osseuse' initiated allogeneic hematopoietic SCT (AHSCT) in Tunisia. As of June 2007, information was collected about 299 patients with a first AHSCT and 12 additional retransplants. The median age was 19 years (range 2-49 years). The main indications were aplastic anemia (n ¼ 106, 36%), leukemia and nonmalignant disorders (n ¼ 153, 51%), Fanconi anemia (n ¼ 26, 9%) and other nonmalignant disorders (n ¼ 14, 4%). Preparative regimens depended on indication. All donors were HLA geno-identical. The stem cell sources were BM (87%) and PBSCs (13%). At the time of analysis, 200 patients (67%) were alive after a median follow-up of 42 months (range 3-112 months). The overall TRM rate was 17%. Outcome depended on indication. According to our results, allogeneic HSCT is potentially curative for hematological diseases, but it is a toxic approach for malignant disorders.
Introduction
Hematopoietic SCT (HSCT) has become the standard treatment for many patients with congenital or acquired disorders of the hematopoietic system. [1] [2] Allogeneic HSCT (AHSCT) is a complex, cost-intensive, therapeutic procedure. Its introduction in Tunisia dates to 1998 and its costs are covered by the social security office or health ministry. We have only one transplant unit for a population of 10 million habitants. The total allogeneic transplants per 10 million habitants have seen a rapid expansion, and at least 40 allogeneic transplant procedures were performed annually (Figure 1 ). Since 2005, we traditionally participate in the European Group for Blood and Marrow Transplantation activity survey and report all HSCT. 3 We report our results after 9 years of activity ( Figures 2-4 ). 
Patients and methods

Data collection
Definitions
First HSCTs were defined according to the criteria of the European Group for Blood and Marrow Transplantation. 4 Additional transplant was defined as follows: retransplant is defined as an unplanned HSCT for rejection or relapse after a first HSCT or multiple transplants, being part of a planned double or triple autologous or allogeneic transplant protocol.
Treatment or TRM was defined as death without relapse.
Statistical analysis
Mean, median and standard deviations of numerical variables were calculated on an Excel spreadsheet. Outcomes measured were overall survival, performed using the Kaplan-Meier estimator and TRM and relapse incidence using cumulative incidence curves. Comparisons were made by log-rank test.
Results
Numbers of AHSCT
In all, there were 299 first allogeneic HSCTs. Twelve patients with myeloma received AHSCT after simple or double autologous transplant. Twelve additional retransplants were performed during the same time period.
Indications for first transplants and donor type
The main indications were aplastic anemia (n ¼ 106, 36%), acute myeloid and lymphoid leukemia (n ¼ 104, 35%), chronic myeloid leukemia (n ¼ 27, 9%), other malignant disorders (n ¼ 22, 8%), Fanconi anemia (n ¼ 26, 9%) and other nonmalignant disorders (n ¼ 14, 4%). All donors were HLA geno-identical. The majority of them (95%) were siblings and the others were other family members (4%) or syngeneic twins (1%).
Stem cell source
The majority of first AHSCTs were BM in 260 patients (87%) and the median number of mononuclear cells was 2.7 Â 10 8 /kg (range 0.67-5.55 Â 10 8 mononuclear cells per kg). There were 39 (13%) PBSC transplants, mainly for advanced diseases and additional retransplants. The median number of CD34 þ cells was 4.2 Â 10 6 /kg (range 1.58-8.4 Â 10 6 CD34 þ cells per kg). All retransplants were PBSC transplants.
Conditioning
Preparative regimens depend on indication. It consisted of a combination of Cy and antithymocyte globulin in aplastic anemia, and a combination of Cy and Bu or TBI for malignant disorders. For patients with Fanconi anemia, we used two consecutive regimens: the first consisted of lowdose Bu and Cy, 5 and the second regimen consisted of fludarabine and Cy. Patients with refractory Hodgkin's lymphoma received planned double transplants, with an autologous transplant first, followed by an allogeneic reduced-intensity conditioning.
Outcome
At the time of analysis and after a median follow-up of 42 months (range 3-112 months), 200 patients were alive (67%) and 99 had died (33%). Causes of death were TRM in 51 (17%) and relapse after transplant in 48 (16%).
Five-year survival, TRM and relapse or graft failure incidence differed for the main disease categories after allogeneic HSCT.
In the nonmalignant hematological disorder group, allogeneic HSCT is a highly effective treatment, with a probability of overall survival at 5 years in 77-82% of patients. Graft rejection (6-19%), infections and GVHD (11-13%) remain areas of significant morbidity and mortality. The TRM rate in this group was 7-18%.
In the malignant hematological disorder group, the probability of overall survival at 5 years was only 45-53%. TRM 
